Ironwood Pharmaceuticals Given New $9.00 Price Target at Cantor Fitzgerald (IRWD)
Analysts at Cantor Fitzgerald decreased their price target on shares of Ironwood Pharmaceuticals (NASDAQ:IRWD) from $10.00 to $9.00 in a research report issued to clients and investors on Wednesday, AR Network reports. The firm currently has a “hold” rating on the stock. Cantor Fitzgerald’s price objective would suggest a potential downside of 10.27% from the stock’s previous close.
A number of other firms have also recently commented on IRWD. Analysts at Zacks reiterated an “outperform” rating on shares of Ironwood Pharmaceuticals in a research note to investors on Wednesday, October 16th. They now have a $13.00 price target on the stock. Separately, analysts at UBS AG cut their price target on shares of Ironwood Pharmaceuticals from $10.50 to $9.00 in a research note to investors on Tuesday, October 15th. They now have a “sell” rating on the stock. Two equities research analysts have rated the stock with a sell rating, eight have assigned a hold rating and seven have given a buy rating to the company. The company currently has an average rating of “Hold” and an average price target of $13.59.
Ironwood Pharmaceuticals (NASDAQ:IRWD) opened at 10.03 on Wednesday. Ironwood Pharmaceuticals has a 52-week low of $9.83 and a 52-week high of $19.67. The stock’s 50-day moving average is $11.89 and its 200-day moving average is $13.81. The company’s market cap is $1.138 billion.
Ironwood Pharmaceuticals (NASDAQ:IRWD) last issued its quarterly earnings data on Tuesday, October 22nd. The company reported ($0.51) EPS for the quarter, beating the Thomson Reuters consensus estimate of ($0.57) by $0.06. The company had revenue of $4.90 million for the quarter, compared to the consensus estimate of $6.54 million. During the same quarter in the prior year, the company posted $0.42 earnings per share. The company’s quarterly revenue was down 94.9% on a year-over-year basis. On average, analysts predict that Ironwood Pharmaceuticals will post $-2.44 earnings per share for the current fiscal year.
Ironwood Pharmaceuticals, Inc is a pharmaceutical company, which discovers, develops and intends to commercialize differentiated medicines.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.